US 12,084,434 B2
Methods for treating cancer
David St. Jean, Jr., Natick, MA (US)
Assigned to Scorpion Therapeutics, Inc., Boston, MA (US)
Filed by Scorpion Therapeutics, Inc., Boston, MA (US)
Filed on Nov. 15, 2023, as Appl. No. 18/509,967.
Application 18/509,967 is a continuation of application No. 18/450,586, filed on Aug. 16, 2023, granted, now 11,897,871.
Application 18/450,586 is a continuation of application No. PCT/US2022/033255, filed on Jun. 13, 2022.
Claims priority of provisional application 63/348,261, filed on Jun. 2, 2022.
Claims priority of provisional application 63/319,236, filed on Mar. 11, 2022.
Claims priority of provisional application 63/316,017, filed on Mar. 3, 2022.
Claims priority of provisional application 63/288,909, filed on Dec. 13, 2021.
Claims priority of provisional application 63/228,351, filed on Aug. 2, 2021.
Claims priority of provisional application 63/210,370, filed on Jun. 14, 2021.
Prior Publication US 2024/0158376 A1, May 16, 2024
Int. Cl. C07D 405/12 (2006.01)
CPC C07D 405/12 (2013.01) 16 Claims
 
1. A method of treating a breast cancer in a human subject, the breast cancer having one or more mutations in PI3Kα, the method comprising administering to the subject a therapeutically effective amount of a compound which is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.